Evidence map›Paper›PMID 41631002›Full record

ArticleGastro hep advances2026

Carbonic Anhydrase-IX Is a Specific and Sensitive Theragnostic Target for Imaging and Radioimmunotherapy in Metastatic Colorectal Cancer.

Dijina Swaroop, Jai Smith, Jessica Van Zuykelom, Asif Noor, Robin A Wagner, Tamara Vu, Sarah Lee, Alexander G Heriot, Benjamin Loveday, Kelly Waldeck and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dijina SwaroopDepartment of Clinical Pathology, Plasticity, Heterogeneity and Tumour Microenvironment International Research Laboratory - PHANTOM - CNRS and The University of Melbourne, Melbourne, Australia.
Jai SmithDepartment of Clinical Pathology, Plasticity, Heterogeneity and Tumour Microenvironment International Research Laboratory - PHANTOM - CNRS and The University of Melbourne, Melbourne, Australia.
Jessica Van ZuykelomResearch Division, Models of Cancer Translational Research Centre, Peter MacCallum Cancer Centre, Victoria, Australia.
Asif NoorSchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Australia.
Robin A WagnerDepartment of Clinical Pathology, Plasticity, Heterogeneity and Tumour Microenvironment International Research Laboratory - PHANTOM - CNRS and The University of Melbourne, Melbourne, Australia.
Tamara VuDepartment of Clinical Pathology, Plasticity, Heterogeneity and Tumour Microenvironment International Research Laboratory - PHANTOM - CNRS and The University of Melbourne, Melbourne, Australia.
Sarah LeeDepartment of Clinical Pathology, Plasticity, Heterogeneity and Tumour Microenvironment International Research Laboratory - PHANTOM - CNRS and The University of Melbourne, Melbourne, Australia.
Alexander G HeriotDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Benjamin LovedayDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Kelly WaldeckResearch Division, Models of Cancer Translational Research Centre, Peter MacCallum Cancer Centre, Victoria, Australia.
Peter D RoseltDepartment of Radiopharmaceutical Sciences, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Benjamin BlythResearch Division, Models of Cancer Translational Research Centre, Peter MacCallum Cancer Centre, Victoria, Australia.
Paul S DonnellySchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Australia.
Frédéric HollandeDepartment of Clinical Pathology, Plasticity, Heterogeneity and Tumour Microenvironment International Research Laboratory - PHANTOM - CNRS and The University of Melbourne, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Over 40% of colorectal cancer (CRC) patients develop metastatic disease. Their survival outlook is very low, highlighting the urgent need to improve the detection and therapeutic management of metastatic colorectal cancer (mCRC), particularly when metastases are not surgically resectable. Our study aimed to characterize the preclinical utility of targeting carbonic anhydrase IX (CA-IX) for metastasis imaging and for therapeutic purposes in patients with CRC liver metastases. Methods: CA-IX expression was characterized in 46 liver metastasis samples using RNA sequencing and immunohistochemical staining. We labeled girentuximab, a clinical grade CA-IX antibody, with zirconium-89 ([ Results: CA-IX mRNA and/or protein expression was detected in 87% of CRC liver metastasis samples, with little to no expression in surrounding liver tissue. Both [ Conclusion: Our results demonstrate that CA-IX is a relevant target for a theragnostic strategy in mCRC, and provide the first demonstration in clinically-relevant models of metastasis that radiolabeled girentuximab can be used as a scouting agent to stratify and monitor mCRC patients and as a therapeutic alternative for patients with CA-IX-expressing tumors.

Indexed as

Bowel CancerLiver MetastasesTheragnostics

Identifiers

PMID41631002
PMCPMC12860988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.